LifeMine Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$60M
Industry:Biotech
Founded:2016
Lead Investor(s):WuXi Healthcare Ventures
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • LifeMine Therapeutics's estimated annual revenue is currently $9.6M per year.
  • LifeMine Therapeutics received $55.0M in venture funding in September 2017.
  • LifeMine Therapeutics's estimated revenue per employee is $155,000
  • LifeMine Therapeutics's total funding is $60M.

Employee Data

  • LifeMine Therapeutics has 62 Employees.
  • LifeMine Therapeutics grew their employee count by 41% last year.
  • LifeMine Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$8.7M5660%N/A
Tango Therapeut...
$12.9M8338%N/A
Compass Therape...
$16.4M10614%N/A
Cell Signaling ...
$89.4M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$15.3M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$17.2M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

LifeMine Therapeutics is pioneering a genomically-enabled drug discovery approach integrating advanced life science and computational technologies to elucidate human biology and create sophisticated therapeutics that attack the fundamental drivers of serious human diseases. LifeMine will access new drug modalities by conducting the first industrial-scale operation exploiting small molecule evolution in fungi to discover game-changing therapeutics. The initial focus will be on immune modulators, metabolic effectors, and cell differentiators. This platform is expected to provide multiple first- and best-in-class therapeutics in succession, and to continue delivering these for years to come. Founder & CEO: Greg Verdine, Erving Professor at Harvard University and Harvard Medical School. Founder of Gloucester Pharmaceuticals (acquired by Celgene), Enanta Pharmaceuticals (NASDAQ: ENTA), Eleven Biotherapeutics (NASDAQ: EBIO), Tokai Pharmaceuticals (NASDAQ: TKAI), WaVe Life Sciences (NASDAQ: WVE), Warp Drive Bio, Aileron Therapeutics, and the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy.

keywords:N/A

62

Number of Employees

$9.6M

Revenue (est)

1

Current Jobs

41%

Employee Growth %

$60M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Soderberg GisellaSenior Human Resources ManagerEmail Available
Philippe ProchassonDirector Of Synthetic BiologyEmail Available
Aric WiestHead of Fermentation
Mohindra SeepersaudDirectorEmail Available
Joe RegoHead Of Facilities
Paul SecristSVP, Head of Discovery ResearchEmail Available
Iain McFadyenChief Data OfficerEmail Available
Uddhav ShigdelPrincipal ScientistEmail Available
Robert GiacobbeSenior Principal ScientistEmail Available
Jian-Qiao GuDirector

LifeMine Therapeutics News

12-Sep-19 - Bulfinch Signs Three New Leases at Cambridge Discovery Park

In June, Bulfinch announced that FogPharma and its affiliate company, LifeMine Therapeutics, both current tenants in CDP's Building 100, will ...

12-Jun-19 - Cambridge Discovery Park Building 400-500 Will be New ...

... Building 400 to its sister company, LifeMine Therapeutics. “FogPharma and LifeMine have grown in leaps and bounds since their operational ...

18-Sep-17 - LifeMine Therapeutics Launches with $55 Million Series A ...

BOSTON, Sept. 18, 2017 /PRNewswire/ -- LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round ...

LifeMine Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-09-19$55.0MAWuXi Healthcare VenturesArticle